Patients’ outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis.
Spoerl S et al. Transfusion. 2016 Nov 18. doi: 10.1111/trf.13883. [Epub ahead of print].

Maintenance Versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma.
Cornell RF et al. Biol Blood Marrow Transplant. 2016 Nov 15. pii: S1083-8791(16)30489-X. doi: 10.1016/j.bbmt.2016.11.011. [Epub ahead of print].

Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma.
Fernández de Larrea C et al. Bone Marrow Transplant. 2016 Nov 21. doi: 10.1038/bmt.2016.299. [Epub ahead of print].

Outcomes of Maintenance Therapy with Bortezomib Post-Autologous Stem Cell Transplantation for Patients with Multiple Myeloma.
Sivaraj D et al. Biol Blood Marrow Transplant. 2016 Nov 14. pii: S1083-8791(16)30488-8. doi: 10.1016/j.bbmt.2016.11.010. [Epub ahead of print].

Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients.
Oostvogels R et al. Bone Marrow Transplant. 2016 Nov 14. doi: 10.1038/bmt.2016.250. [Epub ahead of print].

Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma.
Xu XS et al. Clin Pharmacol Ther. 2016 Nov 17. doi: 10.1002/cpt.577. [Epub ahead of print].